首页> 外文OA文献 >A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-na\uefve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

【2h】

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-na\uefve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

机译：Polo样激酶抑制剂BI 2536在未接受化疗的胰腺外分泌腺癌的初治患者中的随机II期试验-中欧学会抗癌药物研究（CESAR）协作网络中的一项研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Mross, Klaus; Dittrich, Christian; Aulitzky, Walter E.; Strumberg, Dirk; Schufctte, Jochen; Schmid, Roland M.; Hollerbach, Stephan; Merger, Michael; Munzert, Gerd; Fleischer, Frank; Scheulen, Max Ernst;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种 eng
中图分类

相似文献

外文文献
中文文献

1. 来自一项艾日布林联合吉西他滨对比紫杉醇联合吉西他滨作为HER2阴性转移性乳腺癌的一线化疗的II期、多中心、随机试验的包含神经病变相关量表的生活质量结果:韩国癌症研究组试验(KCSG BR13-11) [J] . Ji-Yeon Kim, Young-Hyuck Im, Tae-Yong Kim, 癌症（英文版） . 2019,第008期
2. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). [J] . Schoffski P, Blay JY, De Greve J, European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2010,第12期

机译：polo样激酶1抑制剂BI 2536在晚期头颈癌，乳腺癌，卵巢癌，软组织肉瘤和黑色素瘤患者中的多中心平行II期试验。欧洲癌症研究与治疗组织（EORTC）核心研究所网络（NOCI）的第一个协议。
3. 1260 Multicenter parallel phase II trials of the polo-like kinase 1 inhibitor BI-2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organisation for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI) [J] . P.Sch?ffski, J.Y.Blay, J.DeGreve, European Journal of Cancer Supplements . 2009,第2期

机译：polo样激酶1抑制剂BI-2536在患有晚期头颈癌，乳腺癌，卵巢癌，软组织肉瘤和黑色素瘤的患者中进行的1260多中心平行II期试验。欧洲癌症研究与治疗组织（EORTC）核心研究所网络（NOCI）的第一个协议
4. BBR 3438, a novel 9-aza-anthrapyrazole, in patients with advanced gastric cancer: A phase II study group trial of the central European Society of Anticancer-Drug Research (CESAR) [J] . R.-D. Hofheinz, C. Porta, G. Hartung, Investigational New Drugs . 2005,第4期

机译：BBR 3438，一种新型9-氮杂-蒽吡唑，用于晚期胃癌患者：中欧抗癌药物研究协会（CESAR）的II期研究组试验
5. A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network [O] . K Mross, C Dittrich, W E Aulitzky, 2012

机译：中枢性社会抗癌药物研究（CESAR）协作网络中的一项针对Polo样激酶抑制剂BI 2536在未经化疗的胰腺外分泌腺癌患者中进行的随机II期临床试验
6. A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV [O] . Steinbild, S, Mross, K, Frost, A, 2007

机译：索拉非尼在进行性激素难治性前列腺癌患者中的临床II期研究：CESAR中欧抗癌药物研究协会（EWIV）的研究

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-na\uefve patients with unresectable exocrine adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network

著录项

相似文献

相关主题

期刊订阅